PITTSBURGH, April 6, 2016 — Gateway Analytical announced today that they will be exhibiting and presenting at the upcoming Respiratory Drug Delivery (RDD) conference in Phoenix, Arizona, April 17-20. RDD is an international conference that features in-depth presentations and discussions focused on the latest development in respiratory drug delivery science, in addition to industry networking. During the conference, Gateway Analytical will be promoting a wide array of analytical testing services that focuses on supporting manufacturing quality control, including foreign particulate matter identification, root cause analysis, contaminate source determination, and out-of-specification investigation support. In addition, Gateway will be promoting their unique Raman chemical imaging services that provide drug developers with truly chemically specific particle characterization. This chemical specificity is the key to understanding the extent of agglomerations in orally inhaled drug products (OINDPs), which is critical for safety, stability and FDA submission.
Gateway Analytical Scientist, Emily Landsperger, will be presenting a poster titled “API-Specific Particle Size Distribution and Agglomerate Analysis Using the Rap.ID Single Particle Explorer (SPE),” during the RDD poster session on Active Pharmaceutical Ingredients (API). This poster will present the results of a study that reviewed the API size distribution within the final formulation drug products, including nasal sprays, metered dose inhalers, and dry powder inhalers. Having this knowledge is critical as it relates to bioavailability, rates of absorption, and stability of that drug product. “We are excited about participating in the discussions and presenting our study during the poster session at RDD this year. We recognize that being able to obtain specific information on API’s and agglomerates in a drug product formulation will prove even more critical, as requirements become more stringent for FDA submission in the years to come. With our capabilities, we stand at the forefront of being able to provide this significant information to developers,” said David Exline, Senior Vice President at Gateway Analytical.
Gateway Analytical is a full service, cGMP compliant, ISO 17025:2005 compliant, FDA registered; and inspected laboratory with specialized expertise in techniques for materials analysis and foreign particulate matter contamination identification. For more information on Gateway Analytical pharmaceutical investigation services, contact us at firstname.lastname@example.org or visit our website, www.gatewayanalytical.com.
About Gateway Analytical
Based in Gibsonia, Pa., Gateway Analytical, LLC partners with companies in need of high-quality laboratory analysis that do not have the time, resources or capabilities for specialized, comprehensive testing. Through conventional and innovative testing methods, the company provides expert laboratory services and analytical solutions for the pharmaceutical, forensic and materials science industries.
Gateway Analytical is a subsidiary of ChemImage Corporation, a leader in chemical imaging technology and instrumentation.
ChemImage Corporation, a leader in hyperspectral and Raman chemical imaging technology provides innovative instrumentation, analysis software, contract services and expert consulting to government, industrial and academic organizations. The company’s proprietary, state-of-the-art imaging technology has many applications, including defense, security, pharmaceuticals, forensics and biomedical diagnostic research, which can reveal critical chemical and biological information from a variety of material systems.
ChemImage’s headquarters are located in Pittsburgh, PA, where it pioneers research and development, as well as providing engineering and manufacturing which develops innovative products for the global marketplace.
For more information contact:
Press Contact: Tifanie Tiberio, Marketing Events & Media Manager
5316 William Flynn Highway
Gibsonia, PA 15044
Phone: +1 (724) 443-1900